Early HIV Therapy in Patients With High CD4 Cell Counts (EARLI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01479634|
Recruitment Status : Completed
First Posted : November 24, 2011
Last Update Posted : March 4, 2016
|Condition or disease||Intervention/treatment||Phase|
|HIV||Drug: Standard ART Drug: Study-Provided ART||Not Applicable|
After dramatic progress in recent years, HIV care for patients in resource limited settings is rapidly evolving to newer models of care delivery. Governments, non-governmental organizations and charitable foundations are placing increasing scrutiny on the programmatic costs associated with delivering antiretroviral therapy (ART). Given these realities, if the global ART roll-out is to continue successfully, we must develop innovative new ways of providing HIV care and ART that are more efficient, more cost-effective, and tightly integrated within country-level health systems. We must treat more patients with fewer resources, and we need sustainable simple models for ART delivery.
These goals can be accomplished building on several existing knowledge points. First, initiating ART at earlier disease stages and at higher CD4+ cell counts may prevent irreversible immunologic damage, prevent opportunistic infections and non-AIDS-associated morbidities, and may prevent death. International and national HIV policy bodies have increasingly recognized this and adjusted recommendations in this direction. Second, ART initiation at higher CD4+ cell counts is less complex, triggers fewer complications, and is less costly to healthcare systems. Third, patients responding to therapy and doing well require fewer physician-administered follow-up visits. This can allow for "task-shifting" to non-MD providers, and the establishment of tiered healthcare delivery down the spectrum of medical acuity. Fourth, the lack of viral load monitoring is responsible for major structural problems in how we deliver ART, causing delays in recognizing ART failure, preventing clinicians from diagnosing HIV drug resistance, and making the decision to switch a patient to a new ART regimen very error-prone.
The EARLI study is a pilot study that will address and investigate all of the above critical issues. This study will focus exclusively on asymptomatic patients with CD4 cell counts ≥250 cells/uL. These relatively healthier individuals are well suited to a more streamlined approach to ART delivery and healthcare provision.
A. To evaluate the 48 week efficacy of ART initiated in asymptomatic individuals with high CD4+ cell counts (CD4+ > 250 cells/uL) and provided in a "streamlined" mode of care.
B. To evaluate the programmatic costs of streamlined ART delivery to asymptomatic high CD4+ count individuals.
A. To evaluate the 96 week efficacy of ART initiated in high CD4+ cell count individuals.
B. To identify predictors of retention in care among high CD4+ cell count ART initiators.
C. To assess adverse events among high CD4+ cell count ART initiators.
D. To assess medication adherence among high CD4+ cell count ART initiators.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||279 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Early Antiretroviral Therapy in Resource Limited Settings in Patients With High CD4+ Cell Counts (EARLI)|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||June 2015|
|Actual Study Completion Date :||June 2015|
Active Comparator: Arm A
Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
Drug: Standard ART
Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
Active Comparator: Arm B
Treatment for HIV in participants with CD4+ cell counts >350 cells/uL
Drug: Study-Provided ART
Study provided drugs:
- 48-Week Efficacy [ Time Frame: When all participants reach 48 weeks on study ]Proportion of patients with virologic suppression (HIV-1 plasma RNA ≤400 copies/cc) at 48 weeks, stratified by study arm.
- Programmatic Costs [ Time Frame: When all participants reach 48 weeks on study ]Total estimated costs of provider time, medications, diagnostic testing, and healthcare facility infrastructure per patient treated with ART for one year, stratified by study arm
- 96-Week and 144-Week Efficacy [ Time Frame: When all particiants reach 96 and 144 weeks on study, respectively ]Proportion of patients with virologic suppression (HIV-1 plasma RNA ≤400 copies/cc) at 96 and 144 weeks, stratified by study arm.
- Predictors of Retention in Care [ Time Frame: When all participants reach 48 weeks on study, then again 144 weeks on study ]Factors statistically significantly associated with attendance at all scheduled clinical visits throughout the first 48 weeks of ART, and throughout the full 144 week study period, stratified by study arm.
- Adverse Event Rates [ Time Frame: When all participants reach 48 weeks on study, then again at 144 weeks ]Describe grade 3 or 4 toxicities (defined by NIH DAIDS scale) that occur throughout the first 48 weeks of ART, and throughout the full 144 week study period, stratified by study arm. These will be assessed by active and passive ascertainment and clinical verification, stratified by study arm.
- Medication Adherence [ Time Frame: When all participants reach 48 weeks on study ]Proportion of total medication doses taken by patients at 48 weeks, assessed by pharmacy refill records, stratified by study arm.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01479634
|Bwizibwera Level IV Health Center|
|Bwizibwera, Mbarara district, Uganda|
|Study Chair:||Diane Havlir, MD||University of California, San Francisco, San Francisco, CA, USA|
|Principal Investigator:||Vivek Jain, MD||University of California, San Francisco, San Francisco, CA, USA|
|Principal Investigator:||Moses Kamya, MBChB, MMed, PhD||Makerere University School of Medicine, Kampala, Uganda|